Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded at Barclays

Barclays upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from an equal weight rating to an overweight rating in a research report released on Tuesday morning, MarketBeat Ratings reports.

Several other equities research analysts have also issued reports on the stock. JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Finally, Zacks Research downgraded shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

OTCMKTS BAYRY opened at $11.45 on Tuesday. The business’s fifty day moving average is $9.47 and its 200 day moving average is $8.52. Bayer Aktiengesellschaft has a fifty-two week low of $5.01 and a fifty-two week high of $11.52. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. The company has a market capitalization of $43.82 billion, a PE ratio of -127.21, a price-to-earnings-growth ratio of 5.51 and a beta of 0.66.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.